Introduction
============

Metastatic breast cancer is generally considered an incurable malignancy.[@b1-ce-9-001] The primary goals of treatment have been palliation and disease control, with some therapies providing a limited survival benefit.[@b1-ce-9-001]

Around 10%--17% of breast cancers are defined as triple-negative (TN), ie, absence of estrogen receptor, progesterone receptor, and of overexpression and/or amplification of the *HER2*/*NEU* gene.[@b2-ce-9-001]--[@b8-ce-9-001] These tumors have some similarities with those known as basal-like tumors, since both affect young patients (\<50 years old) and have a higher prevalence in women of African descent, besides being significantly more aggressive, with higher risk of systemic recurrence and death than other breast tumors.[@b3-ce-9-001],[@b4-ce-9-001],[@b9-ce-9-001],[@b10-ce-9-001] The peak risk of recurrence of these tumors happens between the first and third years after diagnosis, and most deaths occur within the first 5 years after therapy starts.[@b3-ce-9-001],[@b8-ce-9-001],[@b11-ce-9-001]

The finding that *BRCA1* mutations are present in a substantial proportion (25%) of patients with TN breast cancer (TNBC) and the similarities of these tumors with the basal-like subtype suggest that the therapeutic approach can be shared between these tumors.[@b4-ce-9-001],[@b12-ce-9-001],[@b13-ce-9-001] Preclinical studies have shown that these tumors are sensitive to alkylating agents, such as mitomycin C and platinum analogues (cisplatin and carboplatin).[@b14-ce-9-001],[@b15-ce-9-001]

Currently, cytotoxic chemotherapy (CT) is the only option of treatment for metastatic TNBC. Women with TNBC do not seem to benefit from endocrine therapy or trastuzumab.[@b14-ce-9-001] Some molecular-targeted therapies have demonstrated efficacy in this subgroup of patients.[@b16-ce-9-001],[@b17-ce-9-001] Bevacizumab (Bev), a monoclonal antibody against vascular endothelial growth factor, used in association with conventional CT was evaluated in randomized studies that included TNBC patients. Results for this subgroup showed a benefit for this medication.[@b16-ce-9-001],[@b17-ce-9-001] Other examples of drugs with potential benefit for TNBC are cetuximab (epidermal growth-factor receptor inhibition)[@b18-ce-9-001] and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition.[@b19-ce-9-001]

Due to the lack of specific information, there are no published evidence-based clinical guidelines with explicit recommendations about which systemic treatment scheme is more appropriate for these patients with advanced TNBC.[@b9-ce-9-001],[@b11-ce-9-001] The clinical impact of molecular-targeted therapy in the TN population is still not clear.[@b20-ce-9-001] Most information about TN patients comes from subgroup analyses of larger trials, and to our knowledge no systematic synthesis of the studies has been performed so far.

The objective of this study was to perform a systematic review of the literature, with a meta-analysis of randomized studies that evaluated the targeted therapies with conventional CT versus conventional CT alone in patients with TNBC (or basal-like tumor).

Methods
=======

Study-selection criteria
------------------------

### Types of studies

Randomized prospective studies that compared targeted therapy combined with conventional CT versus conventional CT alone in patients with TNBC (or basal-like tumor) were included. We included studies that specifically evaluated this population or those in which a separate analysis for the TNBC patients was performed.

### Types of participants

The selected studies included patients with metastatic TNBC.

### Search strategy for identification of studies

A broad search on the main computerized databases was conducted, including Embase, LILACS, Medline, Science Citation Index (SCI), CENTRAL, the National Cancer Institute Clinical Trials Service, and the Clinical Trials Register. In addition, the annual meeting proceedings of the American Society of Clinical Oncology, the San Antonio Breast Cancer Symposium, the American Association for Cancer Research, and the European Society for Medical Oncology were searched. The manufacturer of Bev in Brazil (Roche) was consulted about ongoing studies that had not yet been published or identified.

The search-strategy methodology for randomized controlled trials[@b21-ce-9-001] recommended by the Cochrane Collaboration[@b22-ce-9-001] was used for Medline. We used an adaptation of this same strategy[@b21-ce-9-001] for Embase, and for LILACS we applied the search-strategy methodology reported by Castro et al.[@b23-ce-9-001] An additional search was performed on the SCI database looking for articles that were cited in the included studies. We added the specific terms pertinent to this review to the overall search-strategy methodology for each database.

The overall search strategy was: 1) "breast neoplasms," 2) "triple negative," 3) "chemotherapy," and 4) randomized controlled trial. Searches in electronic databases combined terms 1--4.

If the data regarding the TN population were not available in the original report, we searched many secondary sources and tried to contact the authors of those studies in order to obtain the information.

Critical evaluation of the selected studies
-------------------------------------------

All references retrieved by the search strategies had their title and abstract evaluated by two of the researchers. Every reference with the least indication of fulfilling the inclusion criteria was listed as preselected. We retrieved the complete articles of all preselected references. They were analyzed by two different researchers and included or excluded according to the previously reported criteria. Excluded trials and the reason for their exclusion were listed and checked by a third reviewer. Two reviewers read the included studies, and all data of interest were extracted using a standard formulary. If the TNBC analysis was not reported in the original paper, we looked for it in many different sources, such as secondary publications, meeting publications, and direct contact with authors, among others.

Details regarding the main methodology characteristics empirically linked to bias[@b24-ce-9-001] were extracted, and the methodological validity of each selected trial was assessed by two reviewers (TEAB and OC). Particular attention was given to some items: the generation and concealment of the sequence of randomization; blinding; application of intention-to-treat analysis; sample size predefinition; adverse-event reports; if the trial was multicentric or unicentric; and the sponsorship.

Data extraction
---------------

Two independent reviewers extracted the data. The name of the first author and the year of publication were used to identify the study. All data were extracted directly from the text or calculated from the available information when necessary. The data on all trials were based on the intention-to-treat principle, so they compared all patients allocated to one treatment with all those allocated to the other.

The primary end point was progression-free survival (PFS). Progression was defined as development of new lesions or "unequivocal progression" of existing lesions, as defined by the original researchers. Secondary end points included objective response rate, overall survival (OS), and adverse events (grade ≥3).

Adverse events analyzed were: neutropenia, thrombocytopenia, anemia, febrile neutropenia (hematological); and fatigue, nausea, thromboembolic events, vomiting, rash, left ventricular dysfunction, hand/foot skin reaction, allergic reaction, proteinuria, hypertension, mucositis, neuropathy, headache, bleeding events, and gastrointestinal perforation (nonhematological).

Analysis and presentation of results
------------------------------------

The data were analyzed using the Review Manager 5.0.24 statistical package (Cochrane Collaboration, Oxford, UK).[@b25-ce-9-001] Dichotomous clinical outcomes are reported as risk ratios (RRs) and survival data as hazard ratios (HRs).[@b26-ce-9-001] The corresponding 95% confidence intervals (95% CIs) were calculated, and a significant *P*-value was considered to be less than 5% (*P*\<0.05). Statistical heterogeneity was calculated through the *I*^2^ method (25% was considered low-level heterogeneity, 25%--50% moderate-level heterogeneity, and \>50% high-level heterogeneity).[@b27-ce-9-001],[@b28-ce-9-001]

If time-to-event data were not available in the study's reports, they were then indirectly estimated, using the methods described by Parmar et al.[@b26-ce-9-001] A pooled estimate of the HR was computed by a fixed-effect model according to the inverse-variance method.[@b29-ce-9-001] Thus, for effectiveness or side effects, an HR or RR greater than 1 favors the standard arm (conventional CT), whereas an HR or RR less than 1 favors the experimental treatment (targeted therapy with CT).

If a high level of statistical heterogeneity was found in the meta-analysis, an additional analysis was performed using the random-effects model described by DerSimonian and Laird,[@b30-ce-9-001] which provides a more conservative analysis.

To assess the possibility of publication bias, the funnel-plot test described by Egger et al was performed.[@b31-ce-9-001] When the pooled results were significant, the number of patients needed to treat to benefit one (NNT) was calculated by pooling absolute-risk differences in the trials included in this meta-analysis.[@b32-ce-9-001]--[@b34-ce-9-001] For all analysis, a forest plot was generated to display results.

Results
=======

[Figure 1](#f1-ce-9-001){ref-type="fig"} represents the flow of identification and inclusion of trials, as recommended by the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analysis) statement.[@b35-ce-9-001] In the first search, 215 articles were obtained. Thirty-two studies were selected and retrieved for full-text analysis. Of these studies, 20 were excluded for various reasons, described in [Table 1](#t2-ce-9-001){ref-type="table"}.

The final analysis included twelve trials comprising 2,048 patients. The targeted therapies studied were Bev, sorafenib (Sor), cetuximab, lapatinib, and PARP inhibitors. Some of the included studies[@b18-ce-9-001],[@b36-ce-9-001],[@b37-ce-9-001] did not report the TNBC subgroup analysis in the original article, and this information was obtained at conference presentations and/or other subsequent publications ([Table 2](#t3-ce-9-001){ref-type="table"}). A quality assessment of the included studies is shown in [Table 3](#t4-ce-9-001){ref-type="table"}. According to the funnel-plot[@b31-ce-9-001] analysis, the possibility of publication bias was low for all end points.

Chemotherapy with bevacizumab
-----------------------------

Four studies evaluated Bev plus CT versus CT alone: three in first-line[@b16-ce-9-001],[@b17-ce-9-001],[@b38-ce-9-001]--[@b40-ce-9-001] and one in second-line therapy.[@b41-ce-9-001]--[@b42-ce-9-001] Most of the studies used a dose of Bev of 15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks, depending on the chemotherapy regimen. One three-arm study (AVADO)[@b16-ce-9-001] evaluated Bev at two different doses: one group received Bev 7.5 mg/kg and another 15 mg/kg. We used the 15 mg/kg results to perform this meta-analysis.

Bev was combined with many different CT regimens (paclitaxel, docetaxel, capecitabine, anthracyclines, gemcitabine, and vinorelbine). The results showed a superior PFS in patients who received Bev plus CT compared to CT alone in previously untreated TNBC (fixed effect, HR =0.62; 95% CI 0.51--0.75; *P*\<0.00001; NNT =2) with no significant heterogeneity (*χ*^2^=4.01, degrees of freedom (*df*)=3; *P*=0.26; *I*^2^=25%) ([Figure 2](#f2-ce-9-001){ref-type="fig"}). These studies did not report either the response-rate data or the OS for the TN subgroup.

In the study that evaluated Bev plus CT in second-line therapy, PFS was also superior in the group that received Bev (HR =0.49, 95% CI 0.33--0.74; *P*=0.0006).[@b41-ce-9-001],[@b42-ce-9-001] A non-significant, higher OS was seen for the TNBC patients that received Bev (HR =0.624, 95% CI 0.39--1.007) ([Table 2](#t3-ce-9-001){ref-type="table"}). The proportion of hematologic toxicities was similar between the group that received Bev plus CT compared to the one that received CT alone. Some nonhematologic toxicities reported were more frequent in patients who received Bev plus CT: proteinuria (fixed effect, RR =11.87, 95% CI 3.41--41.32; *P*=0.0001), hypertension (fixed effect, RR =13.72, 95% CI 6.93--27.15; *P*\<0.00001), neuropathy (fixed effect, RR =1.40, 95% CI 1.09--1.79; *P*=0.008), and bleeding events (fixed effect, RR =5.81, 95% CI 1.87--18.01; *P*=0.002). The other nonhematologic toxicities were similar between the groups.

Chemotherapy with sorafenib
---------------------------

One study compared Sor plus CT versus CT in first-line treatment,[@b37-ce-9-001],[@b43-ce-9-001] and two in second-line treatment.[@b1-ce-9-001],[@b36-ce-9-001],[@b44-ce-9-001],[@b45-ce-9-001] In first-line treatment, Sor (400 mg, orally, twice daily) was associated with paclitaxel, and in second-line treatment Sor was associated with gemcitabine or with capecitabine ([Table 2](#t3-ce-9-001){ref-type="table"}). The response rate was not reported for the TNBC subgroup.

PFS was superior for the group treated with Sor in second-line therapy (fixed effect, HR =0.58, 95% CI 0.36--0.93; *P*=0.02; NNT =2). In the pooled overall analysis, PFS remained superior in the group that received Sor versus CT alone (fixed effect, HR =0.69, 95% CI 0.49--0.98; *P*=0.04), regardless of the treatment line ([Figure 3](#f3-ce-9-001){ref-type="fig"}). There was no heterogeneity in this analysis (*χ*^2^=1.15, *df*=2; *P*=0.56; *I*^2^=0%). One study reported the OS data, and there was no difference between the groups.[@b1-ce-9-001],[@b44-ce-9-001],[@b45-ce-9-001]

The proportion of hematologic toxicities was similar between the group that received Sor plus CT compared to the one that received CT alone. Hand/foot skin reaction and mucositis were more frequent in patients treated with Sor plus CT (hand/foot skin reaction fixed effect, RR =5.00, 95% CI =3.30--7.58, *P*\<0.00001; mucositis fixed effect, RR =2.79, 95% CI 1.01--7.72, *P*=0.05). The other nonhematologic toxicities were similar between the groups.

Chemotherapy with cetuximab
---------------------------

Cetuximab plus CT was studied in patients previously treated for metastatic disease in two randomized studies. Cetuximab(400 mg/m^2^ initial dose followed by 250 mg/m^2^ weekly) was combined with irinotecan and carboplatin in one study[@b18-ce-9-001] and with cisplatin in another study[@b46-ce-9-001] ([Table 2](#t3-ce-9-001){ref-type="table"}).

The meta-analysis showed a higher response rate for the CT with cetuximab group versus CT alone (fixed effect, RR =0.85, 95% CI 0.74--0.97; *P*=0.02). There was no heterogeneity in this analysis (*χ*^2^=1.11, *df*=1; *P*=0.29; *I*^2^=10%). Only one study[@b46-ce-9-001] reported complete PFS and OS data for cetuximab. In this study, PFS was higher for the group of patients treated with cetuximab plus CT versus CT alone (HR =0.67, 95% CI 0.47--0.97); OS was similar between the groups (HR =0.82, 95% CI 0.56--1.2). The other study[@b18-ce-9-001] was presented in a conference and did not report PFS or OS data. We contacted the author about these data, but received no answer. The available conference presentation reported medians and stated that there was no statistically significant difference between the groups in either the median PFS (5.1 months versus 4.7 months) or in the median OS (12.3 months versus 15.5 months).

Neutropenia and rash were more frequent in patients who received cetuximab plus CT compared to those that received CT alone (neutropenia fixed effect, RR =1.85, 95% CI 1.36--2.52, *P*\<0.0001; rash fixed effect, RR =16.64, 95% CI 1.02--272.53, *P*=0.05). The other toxicities were similar between the groups.

Chemotherapy with lapatinib
---------------------------

We found only one study evaluating CT plus lapatinib (1,500 mg orally daily)[@b47-ce-9-001] versus conventional CT (paclitaxel) in patients without previous treatment. PFS was similar between the groups (HR =1.25, 95% CI 0.85--1.83).

Chemotherapy with PARP inhibitor (iniparib)
-------------------------------------------

Two studies evaluated CT with PARP inhibitors (iniparib 5.6 mg/kg; intravenous on days 1, 4, 8, and 11 every 21 days) in patients previously treated[@b19-ce-9-001],[@b48-ce-9-001],[@b49-ce-9-001] ([Table 2](#t3-ce-9-001){ref-type="table"}). A pooled analysis of the studies showed a higher response rate favoring the iniparib plus CT group (fixed effect, RR =0.90, 95% CI 0.80--0.10; *P*=0.05) with significant heterogeneity (*χ*^2^=2.94, *df*=1; *P*=0.09; *I*^2^=66%). As planned, a random-effects model analysis was performed to better explore this heterogeneity: in this analysis, the response rate did not reach a statistically significant level (random effects, RR =0.84, 95% CI 0.64--1.11; *P*=0.23).

PFS was higher in the group that received iniparib plus CT (fixed effect, HR =0.75, 95% CI 0.62--0.90; *P*=0.002;NNT =3). There was moderate heterogeneity (*χ*^2^=1.54, *df*=1; *P*=0.21; *I*^2^=35%) ([Figure 4](#f4-ce-9-001){ref-type="fig"}). A random-effects model analysis was performed, and PFS remained favorable to the CT plus iniparib group (random effects, HR =0.72, 95% CI 0.56--0.94; *P*=0.02).

The meta-analysis of OS data favored the group that received iniparib plus CT (fixed effect, HR =0.80, 95% CI 0.65--0.98; *P*=0.03) but with significant heterogeneity (*χ*^2^=2.57, *df*=1; *P*=0.11; *I*^2^=61%) ([Figure 5](#f5-ce-9-001){ref-type="fig"}). The random-effects model analysis for this end point did not reach a significant difference (random effects, HR =0.74, 95% CI 0.49--1.11; *P*=0.14). Hematologic and nonhematologic toxicities were similar between the groups.

Discussion
==========

As a group, patients with TN tumors have a relatively poor outcome and cannot be treated with endocrine therapy or therapies targeted to human epidermal growth factor receptor type 2.[@b50-ce-9-001] Indeed, this group remains a poorly studied one: there are only a few studies designed specifically to evaluate the effect of CT in TNBC.

This systematic review aimed to evaluate the efficacy of different targeted therapies in TNBC. The results of the meta-analysis showed that these patients might benefit from some of these new therapies: there were significant benefits in PFS associated with Bev, Sor, and iniparib, regardless of the line of treatment; however, cetuximab results are inconclusive so far.

A possible effect of targeted therapies on OS could not be drawn from the published literature, as this end point was not consistently reported in most of the original trials for the TNBC population. The only feasible OS meta-analysis was the one derived from the studies that tested iniparib, in which results were heterogeneous and did not reach statistical significance in a random-effects model analysis.[@b30-ce-9-001] Historically, clinical studies in the advanced breast cancer setting have used PFS as the primary end point,[@b51-ce-9-001] but there is still controversy concerning whether it correlates with OS.[@b52-ce-9-001],[@b53-ce-9-001]

In general, the toxicity reported in the studies was expected and not limiting.[@b16-ce-9-001],[@b17-ce-9-001],[@b38-ce-9-001]--[@b40-ce-9-001] Bev plus CT was associated with higher rates of proteinuria, hypertension, neuropathy, and bleeding events; hand/foot skin reaction and mucositis were more common in patients who received Sor plus CT; neutropenia and rash were more frequent in patients who received cetuximab plus CT.

Despite these encouraging results, many unsolved questions remain regarding targeted therapies combined with CT in TNBC patients. There are still no answers for some important points: which is the most suitable chemotherapy scheme for the association, which are the best molecular-targeted therapies, how to determine the ideal treatment sequence, and the real impact of using targeted therapy combined with CT in overall survival.

An important drawback of this study is that most of the data used in the meta-analysis came from subgroups that were not reported in the original publication and were obtained from secondary sources. Also limiting is the lack of important data from many of the included trials. Ideally, new trials should be performed in this specific population, and trials performed with the general breast cancer population should plan and report separately the results for TNBC patients. Studies already published could also make a significant contribution to the understanding of this subject if an analysis was published with data from this subgroup.

Conclusion
==========

Targeted therapy, when associated with conventional CT, demonstrated gain in PFS in patients with TNBC. The results concerning OS are still uncertain.
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###### 

Core evidence clinical impact summary for targeted therapy in triple-negative metastatic breast cancer

  Outcome measure             Evidence                                                                                                                                                                  Implications
  --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease-oriented evidence   Iniparib or cetuximab when associated with the conventional chemotherapy, demonstrated gains in the response rate.                                                        The overall response rate was higher in patients who received the combination of chemotherapy plus iniparib or cetuximab.
  Patient-oriented evidence   Bevacizumab, sorafenib and iniparib plus conventional chemotherapy, showed superiority in the progression-free survival of patients with triple-negative breast cancer.   A significant benefit was found in the progression-free survival using conventional chemotherapy associated with targeted therapy (bevacizumab, or sorafenib and iniparib).
  Economic evidence           Neither a cost effectiveness nor a budgetary impact analysis were performed                                                                                               Neither a cost effectiveness nor a budgetary impact analysis were performed

###### 

Characteristics of the excluded studies

  Study                                Reasons for exclusion
  ------------------------------------ ----------------------------------------------
  Chia[@b54-ce-9-001]                  Metastatic TN subgroup but not randomized
  Curigliano et al[@b55-ce-9-001]      Sunitinib versus QT in one arm
  Berry et al[@b56-ce-9-001]           Stratified patients only by hormone receptor
  Gluz et al[@b57-ce-9-001]            CT in high doses
  Rodenhuis et al[@b58-ce-9-001]       CT in high doses
  Silver et al[@b59-ce-9-001]          Neoadjuvant TN subgroup and nonrandomized
  Bonnefoi et al[@b60-ce-9-001]        Stratified patients only by hormone receptor
  Leone et al[@b61-ce-9-001]           Neoadjuvant CT and nonrandomized
  Torrisi et al[@b62-ce-9-001]         Neoadjuvant CT and nonrandomized
  Ryan et al[@b63-ce-9-001]            Neoadjuvant CT and nonrandomized
  Frasci et al[@b64-ce-9-001]          Neoadjuvant CT and nonrandomized
  Finn et al[@b65-ce-9-001]            Metastatic TN subgroup and nonrandomized
  Wang et al[@b66-ce-9-001]            Metastatic TN subgroup and nonrandomized
  Citron et al[@b67-ce-9-001]          Stratified patients only by hormone receptor
  Garber et al[@b68-ce-9-001]          Neoadjuvant CT and nonrandomized
  Byrski et al[@b69-ce-9-001]          Neoadjuvant CT and nonrandomized
  von Minckwitz et al[@b70-ce-9-001]   Stratified patients only by hormone receptor
  Carey et al[@b71-ce-9-001]           Cetuximab in both groups
  Bhattacharrya et al[@b72-ce-9-001]   Not targeted therapy
  Rugo[@b73-ce-9-001]                  Not targeted therapy

**Abbreviations:** TN, triple negative; CT, chemotherapy.

###### 

Characteristics of the randomized studies that evaluated different schemes of chemotherapy only in the advanced TNBC (or "basal like" tumor) subgroup

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                                                                             Treatment        N (TN)   Response rate   Progression-free survival (months)   Overall survival          Source of data for the TNBC analysis
  ------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- -------- --------------- ------------------------------------ ------------------------- -------------------------------------------------
  Bevacizumabe ± CT                                                                                                                                                                                                                                          

   Miles et al[@b16-ce-9-001]/Miller et al[@b17-ce-9-001]/O'Shaughnessyet al[@b18-ce-9-001],[@b38-ce-9-001]/Robert[@b39-ce-9-001],[@b40-ce-9-001]   1st line CT      232      NR              *E2100*: 5.3 vs 10.6 months\         NR                        SABC, O'Shaughnessy et al[@b38-ce-9-001]
                                                                                                                                                                                              HR =0.49 (0.34--0.70)                                          

                                                                                                                                                    CT + Bev         163                      *AVADO*:\                                                      
                                                                                                                                                                                              Bev~7,5~: 5.4 vs 6.2 months\                                   
                                                                                                                                                                                              HR 0.69 (0.44--1.08)\                                          
                                                                                                                                                                                              Bev~15~: 5.4 vs 8.2 months\                                    
                                                                                                                                                                                              HR 0.53 (0.34--0.84)                                           

                                                                                                                                                                     279                      *RIBBON*-1 (BEV~15~):\                                         
                                                                                                                                                                                              Cape: 4.2 vs 6.1 months\                                       
                                                                                                                                                                                              HR: 0.72 (0.49--1.06)\                                         
                                                                                                                                                                                              AT: 6.2 vs 6.5 months\                                         
                                                                                                                                                                                              HR 0.78 (0.53--1.15)                                           

   Brufsky et al[@b41-ce-9-001],[@b42-ce-9-001]                                                                                                     2nd line         159      18%             Bev~10\ or\ 15~:                                               Subgroup analysis, Brufsky et al[@b42-ce-9-001]

                                                                                                                                                    CT                        41%             2.7 months                           12.6 months               

                                                                                                                                                    CT + Bev                                  6.0 months                           17.9 months               

                                                                                                                                                                                              HR: 0.494 (0.33--0.74)               HR: 0.624 (0.39--1.007)   

  Sorafenibe ± QT                                                                                                                                                                                                                                            

   Hudis et al[@b36-ce-9-001]                                                                                                                       ≤2nd line        50       NR              2.6 months                           NR                        Gelmon et al[@b74-ce-9-001]

                                                                                                                                                    CT                                        3.1 months                                                     

                                                                                                                                                    CT + Sor                                  HR: 0.57 (0.30--1.09)                                          

   Baselga et al[@b1-ce-9-001],[@b44-ce-9-001]/Gomezet al[@b45-ce-9-001]                                                                            ≤2nd line        53       NR              2.5 months                           16.1 months               Subgroup analysis[@b1-ce-9-001]

                                                                                                                                                    QT                                        4.3 months                           17.5 months               

                                                                                                                                                    QT + Sor                                  HR: 0.596 (0.3--1.1)                 HR: 0.98 (0.5--1.89)      

   Gradishar[@b37-ce-9-001]                                                                                                                         1st line         94       NR              5.5 months                           NR                        Rodler et al[@b75-ce-9-001]

                                                                                                                                                    CT                                        5.6 months                                                     

                                                                                                                                                    CT + Sor                                  HR: 0.856 (0.504--1.454)                                       

  Cetuximab ± CT                                                                                                                                                                                                                                             

   O'Shaughnessy et al[@b18-ce-9-001]                                                                                                               ≤2nd line        72                       5.1 months                           12.3 months               O'Shaughnessy et al[@b18-ce-9-001]

                                                                                                                                                    CT                        30%             4.7 months                           15.5 months               

                                                                                                                                                    CT + cetuximab            49%             NS                                   NS                        

   Baselga et al[@b46-ce-9-001]                                                                                                                     ≥1st line        173      10%             1.5 months                           9.4 months                SABC, Baselga et al[@b46-ce-9-001]

                                                                                                                                                    CT                        20%             3.7 months                           12.9 months               

                                                                                                                                                    CT + cetuximab            *P*=0.11        HR: 0.67 (0.47--0.97)                HR: 0.82 (0.56--1.2)      

  Lapatinib ± CT                                                                                                                                                                                                                                             

   Finn et al[@b47-ce-9-001]                                                                                                                        1st line         131      NR              4.8 months                           NR                        Subgroup analysis, Finn et al[@b47-ce-9-001]

                                                                                                                                                    CT                                        4.6 months                                                     

                                                                                                                                                    CT + lapatinib                            HR: 1.25 (0.85--1.83)                                          

  PARP inhibitors                                                                                                                                                                                                                                            

   O'Shaughnessy et al[@b19-ce-9-001]                                                                                                               ≤2nd line        519      30%             4.1 months                           11.1 months               ASCO, O'Shaughnessy et al[@b19-ce-9-001]

                                                                                                                                                    CT                        34%             5.1 months                           11.8 months               

                                                                                                                                                    CT + iniparib                             HR: 0.79 (0.646--0.976)              HR: 0.87 (0.687--1.116)   

   O'Shaughnessy et al[@b48-ce-9-001],[@b49-ce-9-001]                                                                                               ≤2nd line        123      32%             3.3 months                           7.7 months                O'Shaughnessy et al[@b48-ce-9-001]

                                                                                                                                                    CT                        52%             5.9 months                           2.3 months                

                                                                                                                                                    CT + iniparib             *P*=0.02        HR: 0.59 (0.39--0.90)                HR: 0.57 (0.36--0.9)      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CT, chemotherapy; PARP, poly(ADP-ribose) polymerase; Bev, bevacizumabe; Cape, capecitabina; AT, antracycline and taxane; HR, hazard ratio; SABC, San Antonio Breast Cancer Symposium; ASCO, American Society of Clinical Oncology; TN, triple negative; NS, not significant; BC, breast cancer; NR, not reported.

###### 

Methodological characteristics and definition of PFS of original trials

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                            Randomization described   Allocation concealment adequate?   ITT   Sample size calculation showed   Multicentric?   Independent/blinded evaluation   Sponsor    Definition of PFS                                                                               OBS
  -------------------------------------------------------------------- ------------------------- ---------------------------------- ----- -------------------------------- --------------- -------------------------------- ---------- ----------------------------------------------------------------------------------------------- --------------------
  Miller et al[@b17-ce-9-001]                                          Y                         Y                                  Y     Y                                Y               N                                Mixed      Time from randomization to disease progression or death from any cause                          

  Miles et al[@b16-ce-9-001]                                           Y                         Y                                  Y     Y                                Y               N                                Mixed      Time from randomization to disease progression or death from any cause                          

  Robert et al[@b39-ce-9-001],[@b40-ce-9-001]                          Y                         Y                                  Y     Y                                Y                                                Mixed      Time from randomization to disease progression or death from any cause                          

  Brufsky et al[@b41-ce-9-001],[@b42-ce-9-001]                         Y                         Y                                  Y     Y                                Y               Y                                Industry   Time from randomization to disease progression or death from any cause                          

  Hudis et al[@b36-ce-9-001]                                           Y                         N/A                                N/A   N/A                              N/A             N/A                              N/A        N/A                                                                                             Abstract data only

  Baselga et al[@b1-ce-9-001],[@b44-ce-9-001]\                         Y                         Y                                  Y     Y                                Y               N                                Industry   Measured from the date of randomization to the date of first documented disease progression     
  Gomez et al[@b45-ce-9-001]                                                                                                                                                                                                                                                                                                           

  Gradishar[@b37-ce-9-001]                                             Y                         Y                                  Y     N                                Y               Y                                Industry   N/A                                                                                             

  Gradishar et al[@b43-ce-9-001]                                                                                                                                                                                                                                                                                                       

  O'Shaughnessy et al[@b18-ce-9-001]                                   Y                         N/A                                N/A   N/A                              N/A             N/A                              N/A        N/A                                                                                             Abstract data only

  Baselga et al[@b46-ce-9-001]                                         Y                         N/A                                N/A   N/A                              N/A             N/A                              N/A        N/A                                                                                             Abstract data only

  Finn et al[@b47-ce-9-001]                                            y                         Y                                  Y     Y                                Y               Y                                Industry   Time from random assignment until disease progression or death because of disease under study   

  O'Shaughnessy et al[@b18-ce-9-001],[@b48-ce-9-001],[@b49-ce-9-001]   Y                         N/A                                N/A   N/A                              N/A             N/A                              N/A        N/A                                                                                             Abstract data only

  O'Shaughnessy et al[@b18-ce-9-001],[@b48-ce-9-001],[@b49-ce-9-001]   Y                         Y                                  N     Y                                Y               N                                Industry   Time from randomization toconfirmation of disease progression or death                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** Y, yes; N, no; N/A, not available; PFS, progression-free survival; ITT, intention to treat; OBS, observation.
